{"id":39259,"date":"2021-06-30T10:32:45","date_gmt":"2021-06-30T10:32:45","guid":{"rendered":"https:\/\/biomedpharmajournal.org\/?p=39259"},"modified":"2021-07-13T08:25:15","modified_gmt":"2021-07-13T08:25:15","slug":"covid-19-pharmacological-treatment-at-the-udayana-university-hospital-in-april-may-2020","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol14no2\/covid-19-pharmacological-treatment-at-the-udayana-university-hospital-in-april-may-2020\/","title":{"rendered":"COVID-19 Pharmacological Treatment at the Udayana University Hospital in April-May 2020"},"content":{"rendered":"

Introduction<\/strong><\/p>\n

The first case of COVID-19 in Indonesia was reported in March 2019, since then the numbers of cases are increasing until today. Antiviral therapy that has proven efficacy against SARS-CoV-2 has yet to be found, as wellas evidence-based guidelines or management protocols for COVID-19.1<\/sup>The main pharmacological management of COVID-19 cases to date is still based on clinician’s assessment regarding drugs, or what drugs combination might work in\u00a0the COVID-19 case, and not yet based on empirical evidence from clinical trial studies.1<\/sup>There are not many data regarding the drugs that are effective for COVID-19 based on Randomized Controlled Trial (RCT) especially in the early of pandemic. Until now, The Indonesian Ministry of Health has published the third edition of the COVID-19 management protocol in December\u00a02020.2<\/sup> The first edition of the protocol released by the Indonesian Ministry of Health recommends several drug options for COVID-19 cases, ranging from cases with no symptoms to severe symptoms.3<\/sup> However, it is not certain how the recommended pharmacological therapy options work and can help patients with COVID-19.<\/p>\n

Apart from these problems, this protocol has become a guideline for specialized health facilities that treat COVID-19 in several regions in Indonesia. Udayana University Hospital is one of referral hospital for COVID-19 treatment in Bali, Indonesia. Even though the management protocol has been established, evidence-based medicine still needs to be\u00a0applied in the treatment of COVID-19 patients. There is not much data on the drugs used in COVID-19 patients in Indonesia. Descriptive preliminary data can be a first step for the application of evidence-based medical science related to drugs in COVID-19, particularly in Indonesia.<\/p>\n

Considering the need for evidence-based practice and data publication, this study aims to collect data on pharmacological treatmentgiven in COVID-19 patients at the Udayana University Hospital, and discuss the rationalism of its use, to provide an overview of the COVID-19 treatment development in Indonesia.<\/p>\n

Materials and Methods<\/strong><\/p>\n

This study was a descriptive cross-sectional study conducted in September 2020. All data on hospitalized COVID-19 patients at Udayana University Hospital in April-May 2020 were used in this study. Data on age, sex, drugs name, drugs dose, and duration of treatment were obtained from medical records. Univariate analysis was used to present the frequency and percentage of categorical data, as well as mean and standard deviation for normally\u00a0\u00a0distributed numerical data, otherwise median and interquartile rangewere used. Statistical analyses were performed using SPSS version 17 for windows. The research protocol was approved by the Institutional Review Board.<\/p>\n

Results and Discussion<\/strong><\/p>\n

Positive COVID-19 hospitalized cases in April-May 2020 were 95 cases. The age range of cases was 20-73 years, with a median of 32 years (interquartile range\/IQR = 18 years).Malesare more dominant (72.6%) than the females (27.4%). The median length of treatment was 12 days (IQR = 11 days), with the fastest length of treatment was 5 days and\u00a0the longest was 57 days. Referring to the first edition of the COVID-19 management protocol from the Indonesian Ministry of Health, the pharmacological treatment given during treatment is summarized in Table 1.Median duration of treatment for cases is presented in Table 2.<\/p>\n

Table 1: Pharmacological treatment administered during treatment<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Drug<\/strong><\/td>\nDose<\/strong><\/td>\nN (%)<\/strong><\/td>\n<\/tr>\n
Vitamin C<\/td>\nMild: 500 mg tid-qid, orally, for 14 days<\/p>\n

Moderate-severe: 400 mg tid, intravenously<\/td>\n

95 (100)<\/td>\n<\/tr>\n
Chloroquine Phosphate<\/td>\nMild: 500 mg bid, orally, for 12 days<\/p>\n

Moderate: 500 mg bid, orally, for 5-7 days<\/p>\n

Weight: 500 mg bid, orally (days 1-3), followed by 250 mg every 12 hours, orally (days 4-10)<\/td>\n

58 (61.1)<\/td>\n<\/tr>\n
Antibiotics<\/td>\n<\/td>\n38 (40)<\/td>\n<\/tr>\n
Azithromycin<\/td>\nMild: 500 mg uid, orally, for 5 days<\/p>\n

Moderate: 500 mg uid, intravenously or orally, for 5-7 days<\/p>\n

Weight: 500 mg each uid, intravenously, for 5 days<\/td>\n

33 (34.7)<\/td>\n<\/tr>\n
Levofloxacin<\/td>\nMild: 750 mg uid, orally, for 5 days<\/p>\n

Moderate: 750 mg uid, intravenously or orally, for 5\u20137 days<\/p>\n

Weight: 750 mg uid, intravenously, for 5 days<\/td>\n

5 (5,3)<\/td>\n<\/tr>\n
Antivirus<\/td>\n<\/td>\n39 (41.1)<\/td>\n<\/tr>\n
Oseltamivir<\/td>\nMild: 75 mg bid, orally<\/p>\n

Moderate-severe: 75 mg bid, orally<\/td>\n

36 (37.9)<\/td>\n<\/tr>\n
Lopinavir-Ritonavir<\/td>\n400 mg\/100 mg bid, orally, for 14 days<\/td>\n3 (3,2)<\/td>\n<\/tr>\n
Anticoagulants<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Low Molecular Weight Heparin<\/td>\n1 mg\/kgBW bid<\/td>\n2 (2,1)<\/td>\n<\/tr>\n
Other Drugs<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Alprazolam<\/td>\n0.25-0.5 mg tid<\/td>\n1 (1,1)<\/td>\n<\/tr>\n
Amlodipine<\/td>\n5-10 mg uid<\/td>\n3 (3,2)<\/td>\n<\/tr>\n
Clobazam<\/td>\n20-30 mg uid<\/td>\n9 (9,5)<\/td>\n<\/tr>\n
Meropenem<\/td>\n1 g tid<\/td>\n2 (2,1)<\/td>\n<\/tr>\n
Metformin<\/td>\n500 mg tid<\/td>\n3 (3,2)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Table 2: Median length of treatment by drug<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Drug<\/strong><\/td>\nLength of Treatment <\/strong>(days) (median (IQR))<\/td>\n<\/tr>\n
Vitamin C<\/td>\n12 (11)<\/td>\n<\/tr>\n
Chloroquine Phosphate<\/td>\n<\/td>\n<\/tr>\n
Yes<\/td>\n11 (15)<\/td>\n<\/tr>\n
No<\/td>\n15 (8)<\/td>\n<\/tr>\n
Antibiotics<\/td>\n<\/td>\n<\/tr>\n
Azithromycin<\/td>\n15 (19)<\/td>\n<\/tr>\n
Levofloxacin<\/td>\n15 (16)<\/td>\n<\/tr>\n
No<\/td>\n11 (8)<\/td>\n<\/tr>\n
Antivirus<\/td>\n<\/td>\n<\/tr>\n
Oseltamivir<\/td>\n10 (7)<\/td>\n<\/tr>\n
Lopinavir-Ritonavir<\/td>\n(-)<\/td>\n<\/tr>\n
No<\/td>\n14 (10)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Vitamin C<\/strong><\/p>\n

In this study, all cases received vitamin C. Vitamin C was known to be a potent antioxidant with anti-inflammatory and immuno-supportive properties.4,5<\/sup> The role of vitamin C in viral infections is to decrease the pro-inflammatory response, improve epithelial barrier function, clear alveolar fluid, prevent sepsis-related coagulation problems, and as an essential factor in the production of type I interferon as long as the immune system responds to the\u00a0virus.6,7<\/sup>Vitamin C has been found to be effective in the treatment of pneumonia and infections due to its direct inhibitory effect on pathogens, protects the respiratory tract mucosa, and helps improve complaints of upper respiratory tract infections.8,9<\/sup>In relation to the severity of COVID-19 disease, vitamin C was found to reduce the mortality of complications such as ARDS\u00a0and shock in COVID-19 patients, as well as shorten the length of treatment in the Intensive Care Unit (ICU).10,11<\/sup><\/p>\n

The benefits given by vitamin C depend on the dosage. The plasma level required to achieve maximum function of vitamin C as an antioxidant is estimated to be>175 mg\/L (1000 \u00b5mol\/L), ten times higher than the normal physiological levels.12<\/sup> Oral administration results in lower plasma concentrations due to sodium-dependent vitamin C transporter-1 (SVCT1) regulation, making intravenous administration more desirable.12<\/sup>Oral administration of 3\u00a0grams of vitamin C supplementation is safe and effective in dealing with respiratory or systemic infections, but if consumed every 4 hours it will only produce a plasma concentration of around 220 \u00b5mol\/L.13,14<\/sup> For therapeutic purposes, intravenous vitamin C doses of 10-16 grams per day result in plasma levels>1000 \u00b5mol\/L and provide maximum benefits from vitamin C.15<\/sup>Based on our data in Table 1, the intravenous dose of vitamin C given was low, thus the benefits of vitamin C may not be as expected.<\/p>\n

High doses of vitamin C are reported to have minimal side effects. Some studies reported that patients with pneumonia and sepsis, doses as high as 100 grams\/day did not cause diarrhea and other side effects.16,17<\/sup>In this study we found that 3 patients (3.2%) received metformin. It should be noted that high doses of vitamin C can affect the measurement of blood glucose with a glucometer, therefore blood glucose tests should be done in a central laboratory.18<\/sup><\/p>\n

Chloroquine<\/strong><\/p>\n

Chloroquine was given because of its role as an immunomodulator and antiviral. As an immunosuppressant, chloroquine accumulates in lysosomes and influences lysosomal and autophagosome activity in lymphocytes, causing inhibition of lymphocyte function in the immune system, therefore immune system activation does not occur.19\u201323<\/sup> Chloroquine also prevents toll-like receptor activation and inhibits cytokine production by mononuclear\u00a0cells.24,25<\/sup> As an antiviral, previous in vitro studies of chloroquine on SARS-CoV found that chloroquine interferes with ACE2 terminal glycosylation, decreasing ACE2 and SARS-CoV S protein binding affinity, thereby inhibiting SARS-CoV infection.26<\/sup>However, these findings indicate that chloroquine is more appropriate in the early stages of infection, before SARS-\u00a0CoV-2 decreases ACE2 expression and activity.27<\/sup> In addition, chloroquine can inhibit replication of the virusesby interfering the entry of viruses that are mediated by endosomes.28<\/sup><\/p>\n

Although its mechanism of action has been studied, the latest publication of the World Health Organization (WHO) solidarity trial states that hydroxychloroquine has minimal or no effect in hospitalized COVID-19 patients.29<\/sup>Apart from that, the side effects are quite alarming, including\u00a0retinopathy, neuromyopathy, and cardiomyopathy. Chloroquine also is excreted slowly from our body and has long half-life. Based on these data and finding, the risks and benefits to patients must be taken into account when prescribing \u00a0chloroquine for COVID-19 cases.30<\/sup><\/p>\n

The chloroquine dosage for COVID-19 cases is still inconclusive. China recommends a dose of 500 mg twice daily for 7 days for person who has bodyweight more than 50 kg, while for less than 50 kg, the recommendation dose is 500 mg twice daily on the first day followed by 500 mg once daily until day 7. This Chinese recommendation yields a total dosage of 4-7 grams of chloroquine.31<\/sup> Indonesian protocol recommends chloroquine with \u00a0longer duration, ranging from 5-15 days.3\u00a0<\/sup><\/p>\n

Due to the large volume of distribution and the long half-life of chloroquine (32-50 days), the duration of administration is not recommended to exceed 5 days to avoid accumulation in plasma and tissue.32<\/sup>Administration of high doses is also avoided in severe or critical COVID-19 patients, especially those receiving azithromycin and oseltamivir.33<\/sup><\/p>\n

Antibiotics<\/strong><\/p>\n

The administration of azithromycin and levofloxacin in the management protocol made them became of a standard treatment rather than based on the evidence of a bacterial infection.3<\/sup> Until recently, the use of azithromycin has been widely reported in the literature, and is recommended in several COVID-19 management guidelines in various countries.3,27,34\u201336<\/sup> Apart from having antibacterial activity, azithromycin was found to have antiviral and immunomodulatory effects which made this drug a concern in the COVID-19 pandemic.35<\/sup><\/p>\n

As an immunomodulator, azithromycin acts on the inflammatory cascade and signaling processes of cells. Azithromycin was found to decrease mucus hyper secretion and induce relaxation of contracted airway smooth muscle, as well as reduced hyper secretion of proinflammatory like cytokines and chemokines.35,37<\/sup>The antiviral effect of azithromycin is beneficial for various viral infections (zika, ebola, and influenza) in vitro. However, the results of studies on SARS-CoV-2 are still inconclusive.35<\/sup><\/p>\n

The optimal dose of azithromycin for SARS-CoV-2 infection is unknown, but its use is reported to be safe with minimal risk of severe side effects. Side effects of concern include prolonged QT interval, torsade de pointes, ventricular tachycardia, and sudden cardiac death.35<\/sup><\/p>\n

Despite the benefits, the One Health organization seesthe prolonged use of antibiotics contributes to antibiotic resistance.38<\/sup>Within WHO interim guidance, even antibiotics are not recommended as either treatment or prophylaxis, unless there is clinical sign of bacterial\u00a0 coinfection.39<\/sup> In Indonesia, azithromycin and levofloxacin are still included in the December 2020 edition of the COVID-19 patient management protocol.2<\/sup><\/p>\n

Antiviral<\/strong><\/p>\n

The antiviral recommended in Indonesia is oseltamivir or favipiravir. Like antibiotics, this drugs administration is also a standard treatment in Indonesia.3<\/sup>While the administration of both drugs is not recommended by WHO other than for clinical trials, the Indonesian COVID-19 management protocol until the latest edition still includes the administration of oseltamivir or favipiravir.2<\/sup>39<\/sup><\/p>\n

Oseltamivir works by inhibiting neuraminidase, unlike other viruses (such as influenza A and B), SARS-CoV-2 does not have neuraminidase.40<\/sup>The study in Wuhan even reported that oseltamivir had no role and positive outcome for COVID-19 patients.41<\/sup>Guan et al. found oseltamivir did not reduce ICU admission rates, need for ventilators, and mortality rates for COVID-19 patients.42<\/sup>On the other hand, favipiravir increased the degree of relieve, decrease the duration of fever, cough, and viral clearance (median 4 days).43,44<\/sup><\/p>\n

The lopinavir-ritonavir combination (Aluvia) works specifically by inhibiting proteases, particularly the HIV-1 protease. The results of the latest randomized clinical trial showedthat lopinavir-ritonavir 400 mg\/100 mg administration had no benefit in hospitalized COVID-19 patients. Additionally, side effects of diarrhea, nausea, and weakness were frequently reported in patients receiving this regimen.45,46<\/sup><\/p>\n

Clobazam<\/strong><\/p>\n

In addition to the standard COVID-19 drugs, during treatment, 9 patients (9.5%) experienced anxiety disorders that required pharmacological treatment. In this condition, clobazam was given. The interaction between clobazam and chloroquine phosphate should be noted. Clobazam affects the hepatic metabolism of chloroquine phosphate by inhibiting the CYP2D6 enzyme. The consequence of this interaction is prolonged the choloroquine phospate\u2019s half-life, which may increase the risk of chloroquine toxicity.47\u00a0<\/sup><\/p>\n

Conclusion<\/strong><\/p>\n

The COVID-19 pharmacological treatment given during treatment at the Udayana University Hospital is in accordance with the COVID-19 management protocol by the Indonesian Ministry of Health. Administration of chloroquine phosphate, antibiotics, and antivirals during treatment needs to be reconsidered by weighing the benefits and risks, thereby reducing the cost burden and unnecessary drug consumption.<\/p>\n

Acknowledgement<\/strong><\/p>\n

We thank the Director and all Udayana University Hospital authorities who have authorized and assisted in carrying out this research.<\/p>\n

Conflict of Interest<\/strong><\/p>\n

The authors declare no conflict of interests.<\/p>\n

Funding Source<\/strong><\/p>\n

This research did not receive any funding.<\/p>\n

References<\/strong><\/p>\n

    \n
  1. Paumgartten FJR, Oliveira ACAX de. Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues. Cien Saude Colet<\/em>. 2020;25(9):3413\u20139.
    \nCrossRef<\/a><\/li>\n
  2. Erlina Burhan, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A, et al. Pedoman Tatalaksana COVID-19. 3rd ed. Jakarta; 2020.<\/li>\n
  3. Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A, et al. Protokol Tatalaksana COVID-19. 1st ed. Jakarta; 2020.<\/li>\n
  4. Vera JC, Rivas CI, Velasquez F V., Rong Hua Zhang, Concha II, Golde DW. Resolution of the facilitated transport of dehydroascorbic acid from its intracellular accumulation as ascorbic acid. J Biol Chem<\/em>. 1995.
    \n    CrossRef<\/a><\/li>\n
  5. Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017.
    \n    CrossRef<\/a><\/li>\n
  6. Bharara A, Grossman C, Grinnan D, Syed A, Fisher B, DeWilde C, et al. Intravenous Vitamin C Administered as Adjunctive Therapy for Recurrent Acute Respiratory Distress Syndrome. Case Reports Crit Care<\/em>. 2016.
    \n    CrossRef<\/a><\/li>\n
  7. Kim Y, Kim H, Bae S, Choi J, Lim SY, Lee N, et al. Vitamin C Is an Essential Factor on the Anti-viral Immune Responses through the Production of Interferon-\u03b1\/\u03b2 at the Initial Stage of Influenza A Virus (H3N2) Infection. Immune Netw<\/em>. 2013;
    \n    CrossRef<\/a><\/li>\n
  8. Wilson JX. Evaluation of Vitamin C for Adjuvant Sepsis Therapy. Antioxidants and Redox Signaling. 2013.
    \n    CrossRef<\/a><\/li>\n
  9. Maggini S, Maldonado P, Cardim P, Newball CF, Sota Latino ER. Vitamins C, D and Zinc: Synergistic Roles in Immune Function and Infections. Vitam Miner<\/em>. 2017.
    \n    CrossRef<\/a><\/li>\n
  10. Fowler AA, Truwit JD, Hite RD, Morris PE, Dewilde C, Priday A, et al. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients with Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. In: JAMA – Journal of the American Medical Association. 2019.<\/li>\n
  11. Hemil\u00e4 H, Chalker E. Vitamin C can shorten the length of stay in the ICU: A meta-analysis. Nutrients<\/em>. 2019.
    \n    CrossRef<\/a><\/li>\n
  12. Jackson TS, Xu A, Vita JA, Keaney JF. Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circ Res<\/em>. 1998.
    \n    CrossRef<\/a><\/li>\n
  13. Carr AC, Shaw GM, Fowler AA, Natarajan R. Ascorbate-dependent vasopressor synthesis: A rationale for vitamin C administration in severe sepsis and septic shock? Critical Care. 2015.
    \n    CrossRef<\/a><\/li>\n
  14. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, et al. Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use. Ann Intern Med<\/em>. 2004.
    \n    CrossRef<\/a><\/li>\n
  15. Robitaille L, Mamer OA, Miller WH, Levine M, Assouline S, Melnychuk D, et al. Oxalic acid excretion after intravenous ascorbic acid administration. Metabolism<\/em>. 2009.
    \n    CrossRef<\/a><\/li>\n
  16. Hoang BX, Shaw DG, Fang W, Han B. A Possible Application of High Dose Vitamin C in the Prevention and Therapy for Coronavirus Infections. J Glob Antimicrob Resist<\/em> [Internet]. 2020;23:256\u201362. Available from: https:\/\/doi.org\/10.1016\/j.jgar.2020.09.025
    \n    CrossRef<\/a><\/li>\n
  17. Fowler AA, Syed AA, Knowlson S, Sculthorpe R, Farthing D, DeWilde C, et al. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. J Transl Med<\/em>. 2014.
    \n    CrossRef<\/a><\/li>\n
  18. Flannery AH, Bastin MLT, Magee CA, Bensadoun ES. Vitamin C in Sepsis: When It Seems Too Sweet, It Might\u00a0(Literally) Be. Chest. 2017.
    \n    CrossRef<\/a><\/li>\n
  19. Circu M, Cardelli J, Barr M, O\u2019Byrne K, Mills G, El-Osta H. Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells. PLoS One<\/em>. 2017.
    \n    CrossRef<\/a><\/li>\n
  20. Ballabio A, Bonifacino JS. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nature Reviews Molecular Cell Biology. 2020.
    \n    CrossRef<\/a><\/li>\n
  21. Ghislat G, Lawrence T. Autophagy in dendritic cells. Cellular and Molecular Immunology. 2018.
    \n    CrossRef<\/a><\/li>\n
  22. Schrezenmeier E, D\u00f6rner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nature Reviews Rheumatology. 2020.
    \n    CrossRef<\/a><\/li>\n
  23. Rebecca VW, Nicastri MC, Fennelly C, Chude CI, Barber-Rotenberg JS, Ronghe A, et al. PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov<\/em>. 2019.
    \n    CrossRef<\/a><\/li>\n
  24. Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, Chapman HA, et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature<\/em>. 2008.
    \n    CrossRef<\/a><\/li>\n
  25. Van Den Borne BEEM, Dijkmans BAC, De Rooij HH, Le Cessie S, Verweij CL. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-\u03b1, interleukin 6, and interferon-\u03b3 production by peripheral blood mononuclear cells. J Rheumatol<\/em>. 1997.<\/li>\n
  26. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J<\/em>. 2005.<\/li>\n
  27. Wu R, Wang L, Kuo HCD, Shannar A, Peter R, Chou PJ, et al. An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Reports<\/em>. 2020;6(3):56\u201370.
    \n    CrossRef<\/a><\/li>\n
  28. Cassell S, Edwards J, Brown DT. Effects of lysosomotropic weak bases on infection of BHK-21 cells by Sindbis virus. J Virol<\/em>. 1984.
    \n    CrossRef<\/a><\/li>\n
  29. Pan H, Peto R, Karim QA, Alejandria M, Henao-Restrepo AM, Garc\u00eda CH, et al. Repurposed antiviral drugs for COVID-19 \u2013interim WHO SOLIDARITY trial results. medRxiv<\/em> [Internet]. 2020;(October 15):2020.10.15.20209817. Available from: http:\/\/medrxiv.org \/content\/early\/2020\/10\/15\/2020.10.15.20209817.abstract<\/li>\n
  30. Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ. 2020.
    \n    CrossRef<\/a><\/li>\n
  31. China National Health Comission. Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment, 7th ed. 2020.<\/li>\n
  32. Nugrahaningsih DAA, Purnomo E. Chloroquine and hydroxychloroquine for COVID-19 treatment. J Med Sci<\/em> [Internet]. 2020;52(3):11\u201320. Available from: http:\/\/dx.doi.org\/10.19106\/JMedSciSI005203202002
    \n    CrossRef<\/a><\/li>\n
  33. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw open<\/em>. 2020.
    \n    CrossRef<\/a><\/li>\n
  34. Agarwal AD. Azithromycin in coronavirus disease-19: What we know? Open Access Maced J Med Sci<\/em>. 2020;8(T1):92\u20136.
    \n    CrossRef<\/a><\/li>\n
  35. Echeverr\u00eda-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio Cusc\u00f3 M, Ferr\u00e1ndez O, Horcajada JP, et al. Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti Infect Ther<\/em> [Internet]. 2020;00(00):1\u201317. Available from: https:\/\/doi.org\/10.1080\/14787210.2020.1813024
    \n    CrossRef<\/a><\/li>\n
  36. Bleyzac N, Goutelle S, Bourguignon L, Tod M. Azithromycin for COVID-19: More Than Just an Antimicrobial? Clin Drug Investig<\/em> [Internet]. 2020;40(8):683\u20136. Available from: https:\/\/doi.org\/10.1007\/s40261-020-00933-3
    \n    CrossRef<\/a><\/li>\n
  37. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 \u2014 Final Report. N Engl J Med<\/em>. 2020.<\/li>\n
  38. Miranda C, Silva V, Capita R, Alonso-Calleja C, Igrejas G, Poeta P. Implications of antibiotics use during the COVID-19 pandemic: present and future. J Antimicrob Chemother<\/em>. 2020;(Figure 1):2\u20135.
    \n    CrossRef<\/a><\/li>\n
  39. World Health Organization. Clinical Management of COVID-19: Interim guidance [Internet]. 2020. Available from: https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1278777\/retrieve<\/li>\n
  40. Instiaty, Darmayani IGAAPS, Marzuki JE, Angelia F, William, Siane A, et al. Antiviral treatment of COVID-19: a clinical pharmacology narrative review. Med J Indones<\/em> [Internet]. 2020;29(3):332\u201345. Available from: http:\/\/dx.doi.org\/10.13181\/mji.rev.204652
    \n    CrossRef<\/a><\/li>\n
  41. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA – J Am Med Assoc<\/em>. 2020.
    \n    CrossRef<\/a><\/li>\n
  42. Guan W, Ni Z, Hu YYH, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med<\/em>. 2020.
    \n    CrossRef<\/a><\/li>\n
  43. Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis<\/em>. 2020.
    \n    CrossRef<\/a><\/li>\n
  44. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv<\/em> [Internet]. 2020 Jan 1;2020.03.17.20037432. Available from: http:\/\/medrxiv.org\/ content\/early\/2020\/04 \/15\/2020. 03.17.20037432.abstract<\/li>\n
  45. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med<\/em>. 2020.<\/li>\n
  46. Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. Lopinavir\u2013ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet<\/em>. 2020.
    \n    CrossRef<\/a><\/li>\n
  47. Asadi-Pooya AA, Attar A, Moghadami M, Karimzadeh I. Management of COVID-19 in people with epilepsy: drug considerations. Neurol Sci<\/em>. 2020.
    \n    CrossRef<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Introduction The first case of COVID-19 in Indonesia was reported […]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[92],"tags":[],"class_list":["post-39259","post","type-post","status-publish","format-standard","hentry","category-vol14no2"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/39259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=39259"}],"version-history":[{"count":5,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/39259\/revisions"}],"predecessor-version":[{"id":39807,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/39259\/revisions\/39807"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=39259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=39259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=39259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}